Acucela Licenses Gene Therapy from The University of Manchester


SEATTLE–Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, and The University of Manchester, UK (“UoM”), announced today an exclusive license agreement whereby Acucela will develop and commercialize UoM’s human rhodopsin based optogenetic gene therapy1 for the treatment of retinal degenerative disease, including Retinitis Pigmentosa (“RP”).

Subscribe to get the latest news